A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.

被引：0
|
作者：
Lee, E
George, S
Caligiuri, M
Dodge, R
Smith, R
Szatrowski, T
Schiffer, C
机构：
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2256 / 2256
页数：1
相关论文
共 24 条
  • [1] Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
    Lee, EJ
    George, SL
    Caligiuri, M
    Szatrowski, TP
    Powell, BL
    Lemke, S
    Dodge, RK
    Smith, R
    Baer, M
    Schiffer, CA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2831 - 2839
  • [2] A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617
    Chauncey, TR
    Rankin, C
    Anderson, JE
    Chen, IM
    Kopecky, KJ
    Godwin, JE
    Kalaycio, ME
    Moore, DF
    Shurafa, MS
    Petersdorf, SH
    Kraut, EH
    Leith, CP
    Head, DR
    Luthardt, FW
    Willman, CL
    Appelbaum, FR
    LEUKEMIA RESEARCH, 2000, 24 (07) : 567 - 574
  • [3] Dose escalation studies of ara-c (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years:: Final induction results of CALGB 9621.
    Kolitz, JE
    George, SL
    Dodge, RK
    Hoke, E
    Hurd, DD
    Powell, BL
    Velez-Garcia, E
    Caligiuri, MA
    Moore, JO
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    BLOOD, 2001, 98 (11) : 461A - 461A
  • [4] Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALGB 9720).
    Baer, MR
    George, SL
    Dodge, RK
    Cooke, K
    Caligiuri, MA
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Larson, RA
    BLOOD, 1999, 94 (10) : 383A - 383A
  • [5] A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group Study #9617.
    Chauncey, TR
    Rankin, C
    Anderson, JE
    Godwin, JA
    Kalaycio, M
    Moore, DF
    Petersdorf, SH
    Shurafa, MS
    Kraut, EH
    Head, DR
    Slovak, ML
    Willman, CL
    Appelbaum, FR
    BLOOD, 1998, 92 (10) : 231A - 231A
  • [6] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    BLOOD, 2002, 100 (04) : 1224 - 1232
  • [7] A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
    Gruber, A
    Björkholm, M
    Brinch, L
    Evensen, S
    Gustavsson, B
    Hedenus, M
    Juliusson, G
    Löfvenberg, E
    Nesthus, I
    Simonsson, B
    Sjo, M
    Stenke, L
    Tangen, JM
    Tidefelt, U
    Udén, AM
    Paul, C
    Liliemark, J
    LEUKEMIA RESEARCH, 2003, 27 (04) : 323 - 328
  • [8] Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old:: Correlation of outcome with functional MDR (CALGB studies 9720 and 9760).
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    BLOOD, 2001, 98 (11) : 461A - 462A
  • [9] Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621
    Kolitz, JE
    George, SL
    Dodge, RK
    Hurd, DD
    Powell, BL
    Allen, SL
    Velez-Garcia, E
    Moore, JO
    Shea, TC
    Hoke, E
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4290 - 4301
  • [10] Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old:: Preliminary results of CALGB 9621.
    Kolitz, JE
    George, SL
    Hurd, D
    Hoke, E
    Dodge, RK
    Velez-Garcia, E
    Powell, BL
    Moore, J
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    BLOOD, 1999, 94 (10) : 384A - 384A
123